• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Successful SCOPE outcome and iSCIB1+ selection

by chantal | Jul 22, 2025 | iSCIB1+, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Cancer vaccine data due soon; Glymab developments too

by chantal | Jul 10, 2025 | GlyMab, iSCIB1+, Modi-1, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

H125 reaffirms funds are sufficient to deliver key data

by alex | Jan 30, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Poised for several pivotal clinical events in 2025

by chantal | Jan 13, 2025 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Fundraise extends cash into H226 beyond key catalysts

by chantal | Dec 6, 2024 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Genmab strikes second GlyMab deal

by chantal | Dec 4, 2024 | Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Next Entries »

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy